3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
35
Neoplasm Metastasis
10
Recurrence
7
Breast Neoplasms
5
Carcinoma, Transitional Cell
4
Stomach Neoplasms
3
Neoplastic Cells, Circulating
3
Metastatic Castration-resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Neoplasms
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Thrombocytosis
1
Testicular Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
Etoposide
2
Drug Therapy
2
tremelimumab
1
pembrolizumab
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
durvalumab
1
cabozantinib
1
cabazitaxel
1
Paclitaxel
1
Ifosfamide
1
Granulocyte Colony-Stimulating Factor
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Brentuximab Vedotin
1
BEP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Nonseminomatous germ cell tumor
×
cabazitaxel
×
Clear all
NCT02115165
2026-04-06
CABA-GCT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
34 enrolled